Chargement de l’entreprise
Keep exploring
The themes Tempus AI is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Health Information Services
Graded A or B and worth $2B or more: A first, then the largest.
VEEVVeeva Systems Inc.49B $USA+
BTSGBrightSpring Health Services, Inc.14,2B $USA
HNGEHinge Health, Inc.9,8B $USA+
HQYHealthequity, Inc.8,5B $USA+
DOCSDoximity, Inc.5,9B $USB+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
BIIBBiogen Inc.28 oct. 2026BAGraded B, now A
Comment elle gagne de l'argent
- Diagnostic testing75 %
- Data and applications25 %
Les parts du chiffre d'affaires sont des estimations pour nine months ended September 30, 2026, pas des chiffres tirés d'un document officiel.
En concurrence avec
- Caris Life Sciences
Ce qu'elle vend6
Tempus|xT
A test of cancer tissue that looks for gene changes that may help doctors understand a cancer and choose treatment.
Tempus|xF
A blood test that looks for cancer-related genetic material circulating in the blood.
Tempus|xG
Tests that look for inherited gene changes linked to cancer risk and other inherited conditions.
Afficher 3 de plus
Insights
De-identified patient records and research tools that drug and biotechnology companies use to study diseases and develop medicines.
TIME Trial program
A service that helps doctors and drug companies find patients who may qualify for clinical trials.
Next
Software that checks patient information to help care teams spot missed tests or follow-up needs in cancer and heart care.
Qui l'achète4
- Doctors, genetic counselors, and hospitals order tests for patients; insurers, government health programs, patients, or the ordering institution may pay.
- Pharmaceutical and biotechnology companies buy de-identified patient data, research tools, and analysis services.
- Drug companies pay for help identifying patients who may qualify for clinical trials.
- Academic research institutions buy laboratory testing and related research services.
Sur quoi elle repose, et ce qui pourrait la briser
Ce dont l'activité dépend
- 1Its data business depends on continued access to patient records and permission to use and commercialize de-identified data.
- 2Clinical testing revenue depends in part on insurers and government health programs covering tests and paying enough to cover their cost.
- 3Laboratory testing relies on specialized instruments and materials from a limited number of suppliers, including some sole suppliers.
- 4The business depends on hospitals and other healthcare providers sharing data and using Tempus tests and software.
Ce qui pourrait mal tourner
- 1If Tempus loses access to patient data or cannot continue to use and license it, its research data and related services could be affected.
- 2Insurers or government health programs may decline to cover tests, reduce payment, or change reimbursement rules, affecting the amount Tempus collects for diagnostic work.
- 3Changes to rules for laboratory tests and AI-based medical tools could require additional approvals or oversight, delay products, or limit how Tempus can sell them.
À propos de Tempus AI, Inc.
Tempus runs laboratory tests that examine a patient’s cancer or inherited health risks, then connects results with medical records and other patient information. It uses artificial intelligence (AI) to help doctors interpret results and identify possible treatments or clinical trials. Drug and biotechnology companies pay Tempus for de-identified patient data, research tools, and help finding patients for trials.
- Siège
- Chicago, Illinois
- Fondée en
- 2015
- Cotée sur
- Nasdaq
- Clôture de l'exercice
- December 31
Construit à partir des documents déposés par Tempus AI, Inc. auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.
